Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.52 |
| ▸ | MMP13 | P45452 | 16/20 | 0.52 |
| ▸ | MMP1 | P03956 | 14/20 | 0.52 |
| ▸ | MMP9 | P14780 | 13/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | MMP7 | P09237 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503917 | 0.89 | ADAM17 (0.53) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7258553 | 0.82 | KDM4E (0.47) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6507226 | 0.75 | ADAM17 (0.62) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6508472 | 0.73 | ADAM17 (0.76) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7356916 | 0.73 | ADAM17 (0.62) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7356912 | 0.72 | ADAM17 (0.65) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6499544 | 0.71 | ADAM17 (0.77) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7354960 | 0.71 | ADAM17 (0.80) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL2895020 | 0.71 | ADAM17 (0.50) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6754073 | 0.71 | ADAM17 (0.46) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |